The Silverstein Foundation for Parkinson'S with Gba

“Directors jonathan silverstein and natalie silverstein have a family relationship.”

“The form 990 is prepared, using information provided by the foundation, by an independent accounting firm. The 990, as will be filed with the irs, is reviewed by the board prior to its filing with the internal revenue service.”

“The foundation has a conflict of interest policy in place. (a) if the foundation has multiple directors, a director who is directly or indirectly a party to a transaction with the foundation (an "interested director") shall disclose the material facts of the transaction and his or her interest in or relationship to such transaction to the board of directors and to any committee of the board considering such transaction prior to any action by the board or such committee to authorize, approve or ratify such transaction. A director is "indirectly" a party to a transaction if the entity which is a party is an entity in which the director has a material financial interest or of which the director is an officer, director or general partner. (b) the transaction shall be approved in good faith by the board of directors or a committee of the board by the affirmative vote of: (i) a majority of the disinterested directors; or (ii) a majority of all the directors on the board or committee after deciding that the transaction is fair to the foundation as of the time it is authorized by the board or committee. The presence of an interested director or of a director who is otherwise not disinterested may be counted in determining whether a quorum of the board of directors or a committee of the board is present. The board of directors may in its discretion adopt other procedures as the board determines is appropriate to address conflicts of interest.”

“Documents are available upon request.”

“Continue from part iii: we aggressively seek out new cutting edge therapeutic approaches to treating and preventing parkinson's in gba mutation carriers. Through clinicians, scientists and biotech companies, we seek to accelerate research and clinical trials in an effort to rapidly bring new therapeutic options to patients.”

“Continue from part iii: the foundation previously funded the following initiatives that continue to advance the mission of the organization: - prevail therapeutics, a company that the foundation started with asa abeliovich, raised $200 million via private and public financing. Prevail recently announced that enrollment in the pr001 phase 1/2 propel clinical trial is progressing, patient dosing continues, and the company is hopeful that it will remain on track to report interim data on a subset of patients in the second half of 2020. - aspen neuroscience, which was spun out of scripps institute and the lab of world-renowned stem cell researcher dr. Jean loring, raised more than $70 million to study autologous stem cell approaches. Vanqua bio was launched in 2019 based on foundation-funded research being conducted in the laboratory of dr. Dimitri krainc at northwestern university. The company is focused on developing small molecule modulators of lysosomal targets that have genetic linkages to gba pd. Together with q-state biosciences, the foundation launched chamishi therapeutics, a new drug discovery and development company focused on neurodegenerative diseases and other related disorders. The partnership will combine the silverstein foundation's deep scientific knowledge base with q-state's precision medicine platform, disease-relevant cellular assays, and aso (antisense-oligonucleotide) design capabilities. Chamishi is led by jim sullivan, former vice president of pharmaceutical discovery at abbvie.”

“The beginning of year investments and retained earnings were restated by $865,759 to adjust the unrealized gains to actual for the prior period. No other changes or restatements were made.”